Aspen Pledges its Support of Equitable Vaccine Access in Africa
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
and its subsidiaries (collectively “Aspen” or “the Group”)
ASPEN PLEDGES ITS SUPPORT OF EQUITABLE VACCINE ACCESS IN AFRICA – GROUP CHIEF EXECUTIVE’S
ADDRESS TO HIGH-LEVEL SEMINAR ON MANUFACTURING VACCINES IN AFRICA
Shareholders are advised that, on Friday 29 May 2021, Aspen participated in a high-level manufacturing
seminar on manufacturing vaccines in Africa, hosted by South African President Cyril Ramaphosa and
French President Emmanuel Macron.
The dialogue between Presidents Ramaphosa and Macron included discussions with leading scientists and
captains of industry about vaccine solutions for Africa, strengthening the local public health systems,
addressing the pandemic’s impact on Africa and, in particular, how Africa may expand its own
manufacturing capacity to establish security of supply of vaccines across the continent.
In his address to attendees, Aspen Group Chief Executive, Stephen Saad, confirmed that Aspen was
committed to providing impetus to the common global understanding that “we are not safe until we are all
safe”. He also confirmed that it was critical that Africa collaborated with the international community to
ensure security of demand, underwritten through long-term offtakes, and the facilitation of technology
licenses and transfers.
Aspen’s commitment to making sterile manufacturing capacity available for equitable vaccine access to
Africa was reiterated and reference was made to multiple engagements with the African Union, the African
Centre for Disease Control and other key stakeholders on the contributions Aspen could render in this
regard. It was, however, confirmed that this commitment would require a substantial increase of Aspen’s
African sterile capacities.
His address further confirmed that Aspen had been at the forefront of the fight against other global
pandemics including HIV/AIDS, MDR TB and, more recently, COVID-19. Aspen’s contribution to this fight to
date has been through its ongoing supply of dexamethasone and lifesaving anaesthetics, playing a leading
role in this regard throughout Europe and globally. Aspen was, however, shifting its COVID-19 focus to
assist in ensuring equitable access to vaccines for less developed countries, with a particular emphasis on
African countries. While Aspen was able to make the required investments to ensure Africa’s reduced
reliance on the importation of vaccines, there was a need for certainty on sustainable demand, as well as
for assistance with licenses and technology transfers.
Aspen’s full press release in this regard can be accessed on its website at the following link:
31 May 2021
Investec Bank Limited
Date: 31-05-2021 09:15:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.